The world of REMAP-CAP is constantly evolving, here’s what’s new!

REMAP-CAP, a groundbreaking trial that has most recently been primarily focused on finding treatments for COVID-19, has now been selected by the National Institute for Healthcare and Research to evaluate therapeutic interventions for influenza.

New results have recently been published from the ACE2 RAS domain, one of the multiple therapeutic domains within REMAP-CAP, a trial within Spiral’s manifest of studies.

Spiral talks with Ly-Mee Yu, Lead Statistician of the PANORAMIC Trial on the devastating effects of the pandemic and how trials like PANORAMIC, with the help of Spiral’s software, are aiming to provide better health outcomes for those affected by the virus.

After two years of online meetings, attending the Australian Clinical Trials Alliance Annual Science meeting in Adelaide in November felt fantastic. It was a whirlwind of activity, new technology, connections, learning, and, importantly, an excellent opportunity to connect with industry peers.